MedTrace Logo

Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305

NCT00915356 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2012-02-01

Study results available
· View outcomes & findings →

Summary

This study is being carried out to see which dose of AZD1305 is safe and effective in cardioverting atrial fibrillation into normal heart rhythm.

Conditions

Interventions

DRUG

AZD1305

Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes

DRUG

Placebo

iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes

Sponsors & Collaborators

Principal Investigators

  • AZD1305 Medical Science Director · AstraZeneca R&D, Mölndal, Sweden

  • Aladár Rónaszéki · Péterfy HospitalDepartment of Cardiology1076 Budapest, Péterfi Sándor str. 8-20HUNGARY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Czechia
  • Denmark
  • Hungary
  • Netherlands
  • Norway
  • Poland
  • Slovakia
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00915356 on ClinicalTrials.gov